AIRE and pneumonitis: Data in the Aire-deficient mouse from our group and others would suggest that a T-lymphocyte depletion approach such as with the CD52-targeting alemtuzumab would remit APECED pneumonitis (5, 37); however, the risk of opportunistic infections makes such T-cell depleting strategies difficult to implement for the lifelong management of pneumonitis (52, 53).